AZD 8108

Drug Profile

AZD 8108

Alternative Names: AZD8108

Latest Information Update: 06 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Suicidal ideation

Most Recent Events

  • 06 Feb 2017 AstraZeneca divests the development of AZD 8108 to an unknown company (AstraZeneca pipeline, February 2017)
  • 01 Nov 2014 Phase-I clinical trials in Suicidal ideation (In volunteers) in USA (PO)
  • 23 Sep 2014 Preclinical trials in Suicidal ideation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top